Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT07606391
NA

Polidocanol 1% and Steroid in Keloids and Hypertrophic Scars

Sponsor: Sohag University

View on ClinicalTrials.gov

Summary

we will inject intralesional polidocanol 1% in keloids and hypertrophic scars to decrease vascularity and decrease size of lesion compared to intralesional steroid as standard treatment line

Official title: Efficacy and Safety of Intralesional Injection of Polidocanol 1% in Treatment of Keloids and Hypertrophic Scars

Key Details

Gender

All

Age Range

16 Years - 60 Years

Study Type

INTERVENTIONAL

Enrollment

90

Start Date

2026-08-01

Completion Date

2027-08-01

Last Updated

2026-05-26

Healthy Volunteers

No

Interventions

DRUG

Group 1 (polidocanol 1% group):

Patients will receive polidocanol 1 %, a maximum of one milliliter of polidocanol 1% will be injected in each lesion using an insulin syringe with a 24-gauge needle.3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.

DRUG

Group 2 (Triamcinolone acetonide group):

Triamcinolone acetonide will be intralesionally injected at concentration of 20 mg/ml, a maximum of one-milliliter triamcinolone will be injected in the lesion. 3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.

DRUG

Group 3 (combined Triamcinolone acetonide and polidocanol 1% group):

The lesion will be injected 0.1ml/ cm2 Triamcinolone acetonide and 0.1 ml/cm2 polidocanol 1 %, with maximum 1ml Triamcinolone acetonide and 1 ml polidocanol 1 %.3- The active substance will be injected intralesionally every 2 weeks for maximum 6 sessions or complete flattening of the lesion.

Locations (1)

Sohag University

Sohag, Egypt